Hikma Pharmaceuticals plc (HIK.L) Diversifiers

Equity · Currency in GBp · Last updated Jun 5, 2026

Hikma Pharmaceuticals plc develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.

Looking to balance out your exposure to HIK.L? The ETFs below have the lowest correlation with HIK.L — they tend to move on their own, which can help reduce risk when HIK.L drops. The stock ideas table highlights individual companies that behave independently from HIK.L.

Best Diversifiers for HIK.L

1 ETFs have low correlation with HIK.L (below 0.3), 0 of which are negatively correlated. The least correlated is HSBC MSCI World UCITS ETF (HMWO.L) (Global Equities) with a 1Y correlation of 0.29, roughly unchanged from 0.30 over 5 years.

Symbol	Name	Correlation 1Y	Correlation 3Y	Correlation 5Y	Risk / Return Rank	Category	Compare
HMWO.L	HSBC MSCI World UCITS ETF	0.29	0.25	0.30	78	Global Equities	HIK.L vs HMWO.L

Diversification Analysis

Build a portfolio that complements HIK.L

Add HIK.L to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with HIK.L